Hormone replacement therapy has been made out to be the villain for years.
Somewhere along the way, headlines got louder than the science — and fear stuck around longer than the facts did. But here’s the truth: the conversation around hormones has evolved. A lot. We now have decades of additional research, better data, and a much clearer understanding of who benefits, who should avoid therapy, and how to prescribe it safely. I don’t practice medicine based on scary headlines. I practice based on evidence — and on what’s right for the individual sitting in front of me.
There is a persistent belief that HRT is broadly dangerous. That belief largely stems from early interpretations of older studies that have been skewed, misleading, and straight up lied about. Over the past two decades, substantial research has shown a multitude of benefits from HRT and understanding of who benefits, who should avoid therapy, and how it should be managed.
Here’s what the modern evidence consistently shows:
• In appropriately selected patients, hormone replacement therapy is not harmful.
• Timing, formulation, dose, and route of administration matter.
• Risks differ significantly depending on age, health status, and years since menopause or hypogonadism.
• When prescribed thoughtfully and monitored properly, HRT can improve quality of life and may provide protective benefits in certain populations.
Research papers are technical because they are written for physicians and scientists. They are not opinion pieces — they are data analyses. My role is to interpret that data accurately and apply it responsibly to individual patients.
I practice evidence-based medicine. I would not recommend hormone therapy if I believed it posed unjustified risk.
Here are some articles addressing the most common concerns about Hormone Replacement Therapy. Some of these dispel myths. Some of these point out the harms associated with a Lack of hormones. And some of these reiterate the Safety of Hormones.
Women’s Health Initiative:
Link for Tis but a Scratch_A Critical Review of the Womens Health Initiative Evidence Associating Menopausal Hormone Therapy with the Risk of Breast Cancer.PDF
This article critically examines the Women’s Health Initiative narrative that fueled widespread fear of HRT. The authors argue that the breast cancer risk findings were overstated, that estrogen-only therapy actually showed reduced breast cancer risk and mortality, and that the remaining concerns about combination therapy are small, statistically questionable, and often misrepresented.
Estradiol:
Link for Postoperative HRT and Ovarian Cancer.pdf
This nationwide cohort study found that women under 60 who received hormone therapy after ovarian cancer surgery had significantly improved overall survival compared with those who did not. Longer duration of therapy was associated with even greater benefit, suggesting HRT may be safe and potentially supportive after treatment in appropriate patients.
Link for Menopausal HRT and Reduction of All-Cause Mortality and Cardiovascular Disease.PDF
This major review supports the “timing hypothesis”: when HRT is started in healthy women under age 60 or within 10 years of menopause, it is associated with significant reductions in cardiovascular disease and overall mortality. The authors emphasize that major risks are rare and comparable to other common medications.
Link for HRT and the risk of colorectal cancer.pdf
This large population-based study found that women who used oral hormone replacement therapy had a significantly lower risk of developing colorectal cancer. After adjusting for other lifestyle and medication factors, HRT use was associated with an estimated 63% relative reduction in colorectal cancer risk.
Link for HRT After Breast Cancer.pdf
This paper reviews many studies of HRT use after breast cancer and argues the fear of HRT has been amplified by selective interpretation of limited data. It highlights that across multiple studies, breast-cancer mortality was not increased, and that one trial (HABITS) drove much of the concern and showed increased local/contralateral events without increased distant mets or mortality in that discussion. This is a persuasive review and should be paired with primary trials/guidelines for balance.
Link for Hormone Therapy Ovarian Cancer.pdf
This randomized clinical trial found that women treated with hormone therapy after ovarian cancer had significantly improved overall survival and relapse-free survival compared with women who did not receive hormones. Long-term follow-up (19+ years) showed no survival harm and in fact demonstrated a survival advantage, supporting the safety of hormone therapy in appropriately selected ovarian cancer survivors.
Link for Estrogen Therapy Ovarian Carcinoma .pdf
In this randomized trial, women assigned to hormone therapy after epithelial ovarian cancer had better overall survival (reported HR ~0.63) and improved relapse-free survival (HR ~0.67) compared with controls, with long follow-up. This directly supports the statement that, in this context, hormone therapy was not harmful and may even be beneficial.
Link for high-dose estrogens treatment of breast cancer.pdf
This review explains the “estrogen paradox”: estrogen can stimulate some breast cancers, but high-dose estrogen has also been used as treatment, especially after a period of estrogen deprivation or endocrine resistance. It summarizes older and newer clinical experiences and argues safety concerns are often overstated relative to observed outcomes—while acknowledging side effects exist. This can help patients understand that “estrogen = cancer” is too simplistic historically and biologically.
Link for Estrogen Therapy Reduce Total Mortality and Coronary Heart Disease.pdf
This article argues that in women who start estrogen therapy near menopause (often <60), the overall data support cardiovascular and mortality benefit, and that major risks (like VTE) are rare in absolute numbers. It’s not presenting new randomized trial data itself; it’s a clinical-interpretation piece using WHI and other trial summaries, useful for patients who think “all HRT is dangerous.” This article reviews the totality of randomized and observational data and explains the “timing hypothesis”: when estrogen therapy is started in healthy women under age 60 or within 10 years of menopause, it is associated with a reduction in coronary heart disease and overall mortality. It clarifies that the original fear from early Women’s Health Initiative headlines came largely from studying women who were much older and many years past menopause at the time therapy was started. When therapy is initiated earlier — closer to menopause — the cardiovascular effects appear neutral to beneficial, not harmful. The authors also emphasize that major adverse events like blood clots or stroke are rare in absolute numbers, and risk depends on age, timing, formulation, and individual health status.
Link for Estrogen Therapy Ovarian Carcinoma .pdf
In a randomized trial of ovarian cancer survivors assigned to estrogen vs no estrogen, estrogen therapy did not worsen disease-free interval or overall survival; outcomes were similar between groups. This is strong because it’s prospective randomization, and it directly addresses the fear that estrogen automatically triggers relapse in ovarian cancer survivors.
Link for Estrogen replacement therapy endometrial cancer.pdf
This matched study looked at women previously treated for endometrial cancer and found estrogen therapy did not increase recurrence or death; in fact, recurrences were lower in hormone users in this dataset (2 vs 11 in matched groups), though selection bias can’t be excluded. Bottom line: in appropriately selected survivors, estrogen therapy did not appear to worsen outcomes in this study, pushing back against the blanket “estrogen always fuels recurrence” fear.
Link for Estrogen replacement colon cancer.pdf
In a very large American Cancer Society cohort, women who used estrogen replacement therapy had a lower risk of dying from colon cancer, especially current and long-term users (reported RR ~0.71 for ever-use; ~0.55 for current users; and ~0.54 for ≥11 years). This supports the message that estrogen therapy has been associated with colon-protective effects in population studies, while remembering it’s association, not proof of causation.
Link for Estrogen colorectal cancer.pdf
This scientific review explains why colorectal cancer rates differ by sex and summarizes evidence that estrogen signaling (especially via ER-β in the colon) may be protective, especially earlier in tumor development. It cites WHI findings that hormone therapy was associated with a reduced colon cancer risk in that trial and argues timing may influence benefit (the “when you start matters” idea). This is a mechanism + evidence synthesis, not a clinical trial by itself, but it helps patients understand the biology behind the statistics
Dangers of Blocking estradiol in Men:
Link for Steroids and Body Composition, Strength, and Sexual Function in Men.pdf
Estradiol is not a “female hormone” — it is biologically necessary for male bone density, sexual function, metabolic health, and vascular integrity. Suppressing it unnecessarily can cause harm. Estradiol is essential for male bone health. Elegant trial showing many testosterone benefits in men are actually mediated through estradiol. Estrogen deficiency = fat gain, sexual dysfunction, bone loss.
Link for Effects of aromatase inhibition on bone mineral density and bone turnover in older men with low testosterone levels.pdf
Aromatase inhibition worsens insulin sensitivity. Aromatase inhibitors lowered estradiol and caused worsened glucose metabolism.
Link for Low-Dose Estrogen Supplementation Improves Vascular Function in Hypogonadal Men.pdf
Estradiol supports male sexual function. Estradiol levels correlate with libido and erectile function. Estrogen is important for cardiovascular function. Low-dose estrogen improved vascular function in hypogonadal men.
Men with very low estradiol have worse outcomes
Multiple cohort studies show low estradiol is associated with increased mortality and fracture risk.
Blood Too Thick? With TRT
Erythrocytosis is the most common adverse effect
Testosterone-induced erythrocytosis is common and manageable.
Cervi A, Balitsky AK. Testosterone use causing erythrocytosis. CMAJ. 2017.
Link for New Part I Articles_Testosterone treatment and cardiovascular and venous thromboembolism risk_what is new.pdf
TRT does not significantly increase major cardiovascular events when appropriately prescribed.
Myth: “Once you start testosterone replacement therapy (TRT), you’re on it forever.”
Link for Rate Extent and Modifiers of Spermatogenic Recovery After Hormonal Male Contraception_An Integrated Analysis-2.pdf
Suppression of the HPG Axis is Physiologic and Reversible. Exogenous testosterone suppresses luteinizing hormone (LH) and follicle-stimulating hormone (FSH) through negative feedback at the hypothalamic–pituitary–gonadal (HPG) axis. This suppression is expected physiology — not permanent damage. Male hormonal contraceptive trials using supraphysiologic testosterone demonstrate that endogenous sperm production recovers in the vast majority of men after discontinuation. Median time to recovery of sperm concentration ≥20 million/mL: 3–6 months; 90% recovered within 12 months; 95% recovered within 24 months. This demonstrates that even strong pharmacologic suppression is typically reversible.
Link for Anabolic Steroid-Induced Hypogonadism_Diagnosis and Treatment.pdf
Link for Recovery of Spermatogenesis Following Testosterone Replacement Therapy or Anabolic-Androgenic Steroid Use.PDF
Recovery After Testosterone Therapy is Common. Data from anabolic steroid cessation and therapeutic TRT discontinuation show that endogenous testosterone production generally returns over time. Demonstrated recovery of spermatogenesis after discontinuation of exogenous androgens. Recovery typically occurs but may take months depending on duration of exposure. These studies show suppression is duration-dependent, not inherently permanent.
Link for Testosterone Therapy in Men With Hypogonadism_An Endocrine Society Clinical Practice Guideline.pdf
Endocrine Society Guidelines Confirm Reversibility. The Endocrine Society Clinical Practice Guideline acknowledges that testosterone therapy suppresses spermatogenesis during treatment but does not state that suppression is permanent. Instead, fertility concerns are addressed by avoiding TRT in men actively pursuing fertility or by using stimulatory agents such as clomiphene or human chorionic gonadotropin. TRT suppresses spermatogenesis during therapy. Fertility can often be restored after discontinuation.
Link for Clomiphene Citrate Treatment as an Alternative Therapeutic Approach for Male Hypogonadism_Mechanisms and Clinical Implications.pdf
Clomiphene and hCG Can Stimulate Recovery. For men who wish to discontinue TRT and restore endogenous production, pharmacologic stimulation is often effective. Demonstrated restoration of endogenous testosterone production. Demonstrated preservation of intratesticular testosterone and sperm production. These studies show that recovery can be supported if needed.
Why Some Men Stay on TRT Long-Term
Long-term continuation is usually due to:
Persistent underlying primary or age-related hypogonadism
Return of symptoms upon discontinuation
Patient preference for improved quality of life
It is not typically because the therapy permanently “shut down” natural production.
In older men with primary testicular failure, baseline function may already be irreversibly impaired — independent of TRT.
TRT suppresses natural production during use — this is normal physiology.
In most men, endogenous testosterone production recovers after discontinuation.
Recovery time depends on age, baseline function, and duration of therapy.
Pharmacologic support (clomiphene, hCG) can assist recovery when needed.
Long-term use is typically a choice based on symptom recurrence — not permanent damage.
Testosterone:
Link for Testosterone_A Metabolic Hormone in Health and Disease.pdf
This paper reviews evidence that testosterone is deeply involved in metabolic health. Low testosterone is strongly associated with insulin resistance, obesity, metabolic syndrome, and type 2 diabetes, while testosterone therapy in deficient men has been shown to improve body composition, glycemic control, and cardiovascular risk markers.
Link for testosterone-therapy breast-cancer.pdf
This review argues that testosterone is an essential hormone in women and that decades of clinical evidence support its safety. The authors report that testosterone therapy does not increase breast cancer risk and may even be protective in some contexts, particularly when aromatization is controlled.
Link for Is Testosterone Treatment Good for the Prostate.PDF
In a long-term observational study of over 1,300 men treated with testosterone for up to 20 years, the incidence of prostate cancer was no higher than expected in the general population. The authors conclude that with proper screening and monitoring, testosterone therapy appears prostate-safe and may improve early detection through regular surveillance.
Link for colorectal cancer long-term androgen deprivation prostate cancer.pdf
Using SEER-Medicare data, this study found men on long-term ADT had a higher risk of colorectal cancer, and the risk increased with longer duration (example: GnRH agonists ≥25 months HR ~1.31; orchiectomy HR ~1.37 vs no ADT). This supports a “hormone depletion can have downstream risks” message, but it’s still observational and limited to an older Medicare population.
Link for colorectal adenocarcinoma androgen deprivation therapy for prostate cancer.pdf
In a large Swedish population dataset, men receiving androgen deprivation therapy (ADT) for prostate cancer had a higher rate of colorectal cancer than matched cancer-free men (overall CRC HR ~1.27; distal colon adenocarcinoma HR ~1.53 reported). The authors note the pattern doesn’t clearly show a dose-response over time, so it raises concern but doesn’t prove ADT causes CRC. Clinically, it supports the idea that very low androgens may have tradeoffs, and hormone context matters.
Link for Breast Cancer Testosterone Therapy.pdf
This clinic-based study followed women using testosterone pellets (with or without estradiol pellets) and reported fewer invasive breast cancers than expected when compared with large reference populations (SEER, WHI placebo, Million Women Study). It argues that testosterone may be breast-protective, and that adding estradiol did not raise breast cancer incidence in their dataset. Important caveat: it’s observational (not randomized), and the comparison is to external populations, not an internal placebo group.
Progesterone:
Link for progesterone in endometrial cancer.pdf
This review explains that progesterone plays a critical role in opposing estrogen-driven growth in the uterine lining. Progestin therapy has been shown to reverse endometrial hyperplasia and is sometimes used as a fertility-sparing treatment in early-stage endometrial cancer, demonstrating progesterone’s protective role in endometrial tissue.
Link for micronized progesterone.pdf
This modern endocrinology review explains why micronized progesterone is often preferred over synthetic progestins. It has a more favorable safety profile, particularly regarding metabolic effects, clotting risk, and breast cancer risk, and may also provide benefits for sleep, mood, and brain function when taken at night.
Link for In Defense of Progesterone.pdf
This review highlights an important distinction: natural progesterone is not the same as synthetic progestins. The authors summarize evidence showing that bioidentical progesterone does not increase breast cancer risk and may actually be protective compared with commonly used synthetic progestins like medroxyprogesterone acetate.
Hormones aren’t inherently dangerous. They’re powerful — and like anything powerful in medicine, they need to be used thoughtfully.
When we consider timing, dose, formulation, and your unique health history, hormone therapy can be safe. It can be life-improving. In some cases, it may even be protective.
If you’ve been told “hormones are bad” without anyone explaining why — or if you’ve been afraid to even ask about them — let’s have a real conversation. We can look at the data together. We can talk about your goals. And we can make a decision based on facts, not fear.
Because you deserve nuance. Not noise.
